Scientists have created an unprecedented molecular map of autism spectrum disorder, laying the groundwork for the development of targeted therapies in the future. Using artificial intelligence and miniature brain models grown in the laboratory, the researchers determined how genetic mutations alter neural networks in the brain. Published in the journal Science, the study represents a major breakthrough in understanding the biological foundations of the disorder.
For decades, developing effective therapies for autism has been one of the most difficult scientific puzzles, as more than 250 genes have been linked to the spectrum. As a result, targeting each of them and addressing the genetic roots of the disorder was like trying to find one key for hundreds of different locks. The new study, however, shifts the focus from genes directly to proteins — the molecules that physically build and maintain the brain’s structure.
Scientists at the University of California, San Francisco (UCSF), systematically studied how these diverse genetic mutations physically affect protein interactions in the developing brain. In the process, they identified more than 1,800 protein interactions associated with autism. Notably, 87% of these interactions were previously unknown to scientists. As a result, the researchers created the largest molecular map of neuropsychiatric disorders to date.
The new discovery could allow pharmacologists to focus directly on protein interactions, and therefore on neural networks in the brain, rather than attempting to develop hundreds of different gene-targeted drugs. According to the researchers, the findings open up entirely new possibilities for developing medications. Based on the data obtained, the authors have already launched three different research programs.
Experts describe the development as one of the most significant advances in autism research, which is particularly promising for people with so-called severe autism who require 24-hour care. Although the new map may not be equally relevant to all forms of autism, it could also help scientists better understand other disorders in the future. Researchers suggest that studying these protein interactions could also improve the management of conditions such as schizophrenia and obsessive-compulsive disorder.
Despite the enormous enthusiasm surrounding the findings, specialists warn that turning these discoveries into real clinical therapies will take considerable time. As representatives of Autism Speaks explain, developing new medications and testing their safety and effectiveness is a lengthy process. Nevertheless, the path from a genetic discovery to an actual therapy is now much clearer and more realistic.
Amid these scientific advances, some U.S. experts are also raising concerns about political and financial challenges. The U.S. Department of Health and Human Services is currently developing a new strategic plan for autism research, but scientists fear that the Trump administration may shift its focus away from genetic and neurobiological research. In their view, reducing funding for such unprecedented studies and shifting attention toward unproven theories could significantly slow the scientific progress already being made.
